The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

Though the S&P 500 dipped earlier this month, it's important to keep in mind that we're still in a very positive market ...

However, income investors can always be picky about which stocks they buy. The good news is that there are several great ...

Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

This big drugmaker's current challenges present an excellent buying opportunity for forward-thinking investors.

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

In this article, we take a look at six biotech companies focused on bringing drugs to treat obesity to the market.